This page contains brief details about the drug , it's indication, dosage & administaration, mechanism of action, related brands with strength, warnings and common side effects.

Background and Date of Approval

Pegylated Interferon Beta-1A is an immunomodulatory agent which was approved for its medical use on 18th August 2014.

Mechanism of Action of undefined

Pegylated Interferon Beta-1A Injection belongs to the class of immunomodulators. Interferons are naturally occurring proteins that release in response to viral infections and pathogens. Pegylated Interferon Beta-1A directly binds to the receptors on the surface of cells and drastically reduces inflammation, thus slowing down the progression of disease and preventing its relapse.

Uses of undefined

Pegylated Interferon Beta-1A Injection has been developed to treat adults with relapsing forms of multiple sclerosis like clinically isolated syndrome, relapsing-remitting disease and active secondary progressive disease.

undefined Drug administaration and Dosage available

Pegylated Interferon Beta-1A is available as a prefilled pen device for injection, intended for subcutaneous administration. It is available in the doses 63/94mcg and 125mcg. The usual dosing schedule is 63mcg on the first day, 94mcg on day 15 and 125mcg on day 29.

Warnings, Precautions and Side Effects of undefined


Contact your doctor immediately if you experience dizziness, fever, or infection. During the Pegylated Interferon Beta-1A injection treatment, your doctor may periodically monitor your blood pressure, blood sugar, electrolytes, heart, liver and kidney parameters to prevent serious complications. Report to your doctor if you have been diagnosed with other autoimmune disorders, depression, seizures, thyroid disorders or problems in your heart, liver or kidneys. Patients with severe liver and kidney impairment should exercise caution while using this medicine. Do not use this injection if you are allergic to interferon beta, rubber or latex.


Pegylated Interferon Beta-1A is probably unsafe for use during pregnancy. Tell your physician before starting this treatment if you are pregnant, think you might be pregnant or planning to have a baby. It is not known if Pegylated Interferon Beta-1A passes into the breastmilk. However, it is advisable to tell your physician before starting this treatment if you are a breastfeeding mother or planning to breastfeed your child.

Side Effects

The common side effects that are likely to occur while you are on the treatment with Pegylated Interferon Beta-1A Injection are injection site reactions, chills, fever, headache, muscle pain, asthenia, pruritus, injection site pain, etc. If you experience any allergic reactions or discomfort after taking this injection, report to your doctor immediately.

Word Of Advice

Eat a well-balanced diet. If you feel dizzy or tired, you should avoid driving or handling machines. Do not touch or rub your skin after injecting this medicine. Wear loose-fitting clothes to avoid discomfort.

Frequently Asked Question


1. Biogen Inc., US Food & Drug Administration, [Revised on Mar 2022] [Accessed on 30th Sep 2022],

2. Claus Madsen, The innovative development in interferon beta treatments of relapsing-remitting multiple sclerosis, Brain and Behavior, 2017, 7:e00696,


The drug information on this page is not a substitute for medical advice, it is meant for educational purposes only. For further details consult your doctor about your medical condition to know if you are eligible to receive this treatment.